Start with the reason for treatment
At the September 2026 check, tesamorelin (EGRIFTA SV, EGRIFTA WR) had approval to reduce excess belly fat for adults who have HIV and lipodystrophy.
HIV is a virus; this approval concerns adults living with it.
Lipodystrophy is a change in where fat gathers in the body, sometimes linked with HIV treatment.
The drug label excludes treatment for weight loss.
So the first question is about the health problem, before the choice of service.
Bring the question to a care visit
If there is already a team managing your HIV care, bring the tesamorelin question to that visit.
For another in-person route, ask a licensed clinic how it assesses this request.
For an online visit, ask who will treat you: a doctor or another licensed health professional. Ask how that person reviews your health history and arranges any local tests.
There is no need to know the jargon before asking for an explanation.
Keep this in mind
Start with the condition and the exact product; then work through the checks and the full cost.